Merck-AstraZeneca Stop Keytruda/Lynparza Combo Trial In Prostate Cancer Patients

Merck & Co Inc MRK will stop the Phase 3 KEYLYNK-010 trial investigating Keytruda combined with Lynparza for metastatic castration-resistant prostate cancer (mCRPC).
The trial included mCRPC patients who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide.
After a planned interim analysis, Merck is discontinuing the study following an independent Data Monitoring Committee (DMC) recommendation.
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS) compared to the control arm of either abiraterone acetate or enzalutamide.
Related: AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer.
The trial's other dual primary endpoint, radiographic progression-free survival (rPFS), was evaluated at an earlier interim analysis and did not demonstrate improvement compared to the control arm.
Merck has an extensive clinical development program in prostate cancer, evaluating Keytruda as monotherapy and in combination with Lynparza and other anti-cancer therapies.
Price Action: MRK shares are down 0.14% at $77.67, and AZN shares are up 0.68% at $60.80 during the premarket session on the last check Tuesday.